Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002)

Two interim and one final statistical analyses were planned for and conducted during this study: * Interim Analysis 1 (futility analysis), * Interim Analysis 2 (\~18 months into study): database cutoff date 12-May-2014, and * Final Analysis (\~36 months into study): database cutoff date 16-Nov-2015. The End of Trial Analysis for the study was conducted at \~75 months into the study: database cutoff date 31-Jan-2019.